SYRS — Syros Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $134.71m
- $36.41m
- $9.94m
Annual cashflow statement for Syros Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -75.4 | -84 | -86.6 | -94.7 | -165 |
| Depreciation | |||||
| Non-Cash Items | 8.71 | 11.6 | -5.4 | -25.9 | 47.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.75 | 12.1 | -10.6 | -5.52 | 5.05 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -60.3 | -57.4 | -99.5 | -123 | -110 |
| Capital Expenditures | -12.6 | -3.34 | -1.25 | -1.24 | -0.272 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.904 | 50 | -51.4 | 68.4 | 37.6 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -11.7 | 46.7 | -52.7 | 67.2 | 37.3 |
| Financing Cash Flow Items | — | -0.207 | -0.041 | 11.7 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 66 | 143 | 70.5 | 131 | 43.5 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -6 | 132 | -81.7 | 75.2 | -28.9 |